Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Product revenues	$ 7,697	$ 4,861	$ 20,415	$ 16,434
Service revenues	6,262	2,387	12,277	6,375
Total revenues	13,959	7,248	32,692	22,809
Cost of sales	5,210	2,325	10,890	7,025
Gross profit	8,749	4,923	21,802	15,784
Operating expenses:
Selling, general and administrative	6,487	4,114	18,074	13,278
Research and development	2,399	1,822	6,524	5,682
Change in fair value of contingent consideration	878		933
Total operating expenses	9,764	5,936	25,531	18,960
Operating loss	(1,015)	(1,013)	(3,729)	(3,176)
Interest expense, net	(94)	(7)	(203)	(16)
Other income (loss), net	30	18	(37)	12
Loss before taxes	(1,079)	(1,002)	(3,969)	(3,180)
Income tax benefit (expense), net	32	302	(72)	899
Net loss	(1,047)	(700)	(4,041)	(2,281)
Less: Net income attributable to non controlling interests	30		38
Net loss attributable to ChyronHego shareholders	$ (1,077)	$ (700)	$ (4,079)	$ (2,281)
Net loss per share attributable to ChyronHego shareholders - basic (in Dollars per share)	$ (0.04)	$ (0.04)	$ (0.17)	$ (0.13)
Net loss per share attributable to ChyronHego shareholders - diluted (in Dollars per share)	$ (0.04)	$ (0.04)	$ (0.17)	$ (0.13)
Weighted average shares outstanding:
Basic (in Shares)	30,236	17,023	23,576	16,910
Diluted (in Shares)	30,236	17,023	23,576	16,910